ArticleACS omega2020
Simultaneous Delivery of antimiR-21 and Doxorubicin by Graphene Oxide for Reducing Toxicity in Cancer Therapy.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Graphene-Based Nanosystem for Targeted Delivery of Anti-Sense miRNA-21 on Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2026Article
- Engineered Sustainable Mxene-PVA Hydrogel as an Inspiring Co-Delivery Carrier for Targeting Solid Tumors.Pharmaceutics · 2025Article
- Stimuli-responsive Graphene-polysaccharide Nanocomposites for Drug Delivery and Tissue Engineering.Current organic synthesis · 2025Review
- Activation of the cGAS-sting Pathway Mediated by Nanocomplexes for Tumor Therapy.Current pharmaceutical design · 2025Review
- Poly(ethylene glycol)-Engrafted Graphene Oxide for Gene Delivery and Nucleic Acid Amplification.Materials (Basel, Switzerland) · 2023Review
- Nanoparticles in Medicine: Current Status in Cancer Treatment.International journal of molecular sciences · 2023Review
- Temperature-Ion-pH Triple Responsive Gellan Gum as In Situ Hydrogel for Long-Acting Cancer Treatment.Gels (Basel, Switzerland) · 2022Article
- Characteristics of Graphene Oxide for Gene Transfection and Controlled Release in Breast Cancer Cells.International journal of molecular sciences · 2022Review
- Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.Small methods · 2021Review
- A Targeted Nano Drug Delivery System of AS1411 Functionalized Graphene Oxide Based Composites.ChemistryOpen · 2021Article
- Graphene Oxide-Induced Protein Conformational Change in Nasopharyngeal Carcinoma Cells: A Joint Research on Cytotoxicity and Photon Therapy.Materials (Basel, Switzerland) · 2021Article
- Advances in Drug Delivery Nanosystems Using Graphene-Based Materials and Carbon Nanotubes.Materials (Basel, Switzerland) · 2021Review
- Functionalized Graphene Platforms for Anticancer Drug Delivery.International journal of nanomedicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graphene oxide (GO) has been studied by many researchers for its potential drug-delivery value. In order to reduce the side effects of anticancer drugs by decreasing the dosage and maintain the therapeutic effects, a dual drug-delivery system that used GO as a carrier and simultaneously loaded with antitumor drugs and antimir-21 was rationally designed for the cooperative treatment of tumors. Results obtained from our studies have found that MDA-MB-231 cells were inhibited in low Dox dose. The outcomes of confocal microscopy indicated that Dox and antimiR-21 could be released rapidly in cancer cells, which is good for killing cancer cells. In addition, qRT-PCR further demonstrated that miR-21 was silenced by antimiR-21. Consequently, GO has a great potential to codeliver chemotherapeutic drugs and gene drugs in cancer combination therapy for reducing toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.